Pancreatic Cancer Research

ResearcherFred Hutch Cancer CenterActive in the last 2 years

Diane M. Simeone

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5142-3087; OpenAlex author ID A5030459924; NIH RePORTER profile ID 1886388. Sources: funder_awards.

Their work

Papers
89 (first author 8, last author 21)
Trials
1
Grants
9
Labs led
5
Collaborators
361
Papers, trials and grants by year

2010: 1 grant · 2011: 5 papers · 2012: 6 papers · 2013: 8 papers · 2014: 9 papers, 1 grant · 2015: 5 papers, 1 grant · 2016: 4 papers, 1 grant · 2017: 2 papers, 1 grant · 2018: 4 papers · 2019: 3 papers, 1 grant · 2020: 4 papers, 1 trial · 2021: 9 papers, 1 grant · 2022: 4 papers · 2023: 9 papers · 2024: 9 papers, 1 grant · 2025: 4 papers · 2026: 4 papers, 1 grant

Papers 50 of 89

  1. Pancreatic Cancer Early Detection Biomarkers for High-Risk Individuals: Insights From the PRECEDE Consortium. Co-author DOI 10.1002/ijc.70592↗
  2. Clonal heterogeneity in human pancreatic ductal adenocarcinoma and its impact on tumor progression. Last author DOI 10.1038/s41588-026-02779-5↗
  3. Validation of a Serum-Based Biomarker Signature for Detection of Early-Stage Pancreatic Ductal Adenocarcinoma. First author DOI 10.1053/j.gastro.2025.08.034↗
  4. Nectin-4 reduces T cell effector function and is a therapeutic target in pancreatic cancer. Co-author DOI 10.1172/jci.insight.194290↗
  5. Longitudinal assessment of disparities in pancreatic cancer care: A retrospective analysis of the National Cancer Database. Co-author DOI 10.1002/wjs.12431↗
  6. Identification of patients at risk for pancreatic cancer in a 3-year timeframe based on machine learning algorithms. Co-author DOI 10.1038/s41598-025-89607-8↗
  7. Areas of Uncertainty in Pancreatic Cancer Surveillance: A Survey Across the International Pancreatic Cancer Early Detection (PRECEDE) Consortium. Co-author DOI 10.1200/po-25-00696↗
  8. A High Performing Biomarker Signature for Detecting Early-Stage Pancreatic Ductal Adenocarcinoma in High-Risk Individuals. Co-author DOI 10.3390/cancers17111866↗
  9. The role of family history in predicting germline pathogenic variant carriers who develop pancreatic cancer: Results of a multicenter collaboration. Co-author DOI 10.1002/cncr.35383↗
  10. Multi-parametric atlas of the pre-metastatic liver for prediction of metastatic outcome in early-stage pancreatic cancer. Co-author DOI 10.1038/s41591-024-03075-7↗
  11. Targeting pancreatic cancer metabolic dependencies through glutamine antagonism. Co-author DOI 10.1038/s43018-023-00647-3↗
  12. UPF1 deficiency enhances mitochondrial ROS which promotes an immunosuppressive microenvironment in pancreatic ductal adenocarcinoma. Co-author DOI 10.1073/pnas.2401996121↗
  13. Surveillance of Individuals at High Risk of Developing Pancreatic Cancer: A Prevalence Meta-analysis to Estimate the Rate of Low-yield Surgery. Co-author DOI 10.1097/sla.0000000000006094↗
  14. Progression of Site-specific Recurrence of Pancreatic Cancer and Implications for Treatment. Co-author DOI 10.1097/sla.0000000000006142↗
  15. Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the T… Co-author DOI 10.1158/2326-6066.cir-23-1073↗
  16. Somatic Mutational Analysis in Endoscopic Ultrasound-Guided Biopsy of Pancreatic Adenocarcinoma: Assessing Yield and Impact. Co-author DOI 10.14309/ajg.0000000000002786↗
  17. The Pancreatic Cancer Early Detection (PRECEDE) Study is a Global Effort to Drive Early Detection: Baseline Imaging Findings in High-Risk Individuals. Last author DOI 10.6004/jnccn.2023.7097↗
  18. A systematic review and meta-analysis of germline BRCA mutations in pancreatic cancer patients identifies global and racial disparities in access to genetic te… Co-author DOI 10.1016/j.esmoop.2023.100881↗
  19. Are All Cysts Created Equal?: Pancreatic Cystic Neoplasms in Patients with Familial or Genetic Risk Factors for Pancreatic Cancer. Last author DOI 10.1016/j.giec.2023.03.002↗
  20. Single-cell RNA sequencing reveals the effects of chemotherapy on human pancreatic adenocarcinoma and its tumor microenvironment. Last author DOI 10.1038/s41467-023-36296-4↗
  21. Author Correction: Single-cell RNA sequencing reveals the effects of chemotherapy on human pancreatic adenocarcinoma and its tumor microenvironment. Last author DOI 10.1038/s41467-023-39680-2↗
  22. Racial, Ethnic, and Sex-based Disparities among High-risk Individuals Undergoing Pancreatic Cancer Surveillance. Co-author DOI 10.1158/1940-6207.capr-22-0529↗
  23. POLQ inhibition elicits an immune response in homologous recombination-deficient pancreatic adenocarcinoma via cGAS/STING signaling. Last author DOI 10.1172/jci165934↗
  24. Gallium-68-labeled fibroblast activation protein inhibitor-46 PET in patients with resectable or borderline resectable pancreatic ductal adenocarcinoma: A phas… Co-author DOI 10.1371/journal.pone.0294564↗
  25. A Blueprint for a Comprehensive, Multidisciplinary Pancreatic Cancer Screening Program First author DOI 10.14309/ajg.0000000000002534↗
  26. Advancing Clinical Trial Innovation in Pancreatic Cancer: A Conversation Between Diane Simeone, Ken Herrmann, and Johannes Czernin. Co-author DOI 10.2967/jnumed.123.265432↗
  27. Standardization of EUS imaging and reporting in high-risk individuals of pancreatic adenocarcinoma: consensus statement of the Pancreatic Cancer Early Detectio… Co-author DOI 10.1016/j.gie.2021.10.025↗
  28. Pancreatic Cancer: Pathogenesis, Screening, Diagnosis, and Treatment. Last author DOI 10.1053/j.gastro.2022.03.056↗
  29. Proteomes of Extracellular Vesicles From Pancreatic Cancer Cells and Cancer-Associated Fibroblasts. Co-author DOI 10.1097/mpa.0000000000002115↗
  30. Standardization of MRI Screening and Reporting in Individuals With Elevated Risk of Pancreatic Ductal Adenocarcinoma: Consensus Statement of the PRECEDE Consor… First author DOI 10.2214/ajr.22.27859↗
  31. Cancer surveillance awareness and practice among families at increased risk for pancreatic adenocarcinoma. Last author DOI 10.1002/cncr.33500↗
  32. A novel target for combination immunotherapy in pancreatic cancer: IL-1β mediates immunosuppression in the tumour microenvironment. First author DOI 10.1038/s41416-021-01303-2↗
  33. Impact of changing guidelines on genetic testing and surveillance recommendations in a contemporary cohort of breast cancer survivors with family history of pa… Co-author DOI 10.1038/s41598-021-91971-0↗
  34. Recommendations for a More Organized and Effective Approach to the Early Detection of Pancreatic Cancer From the PRECEDE (Pancreatic Cancer Early Detection) Co… Co-author DOI 10.1053/j.gastro.2021.08.036↗
  35. Ultra-low Input Circulating Tumor DNA Detection by MED-Amp in Early-Stage Pancreatic Cancer Co-author DOI 10.1101/2021.03.28.437388↗
  36. ATDC binds to KEAP1 to drive NRF2-mediated tumorigenesis and chemoresistance in pancreatic cancer. Last author DOI 10.1101/gad.344184.120↗
  37. The biological underpinnings of therapeutic resistance in pancreatic cancer. Last author DOI 10.1101/gad.348523.121↗
  38. Synergistic targeting and resistance to PARP inhibition in DNA damage repair-deficient pancreatic cancer. Co-author DOI 10.1136/gutjnl-2019-319970↗
  39. Clinical and genomic characterisation of mismatch repair deficient pancreatic adenocarcinoma. Co-author DOI 10.1136/gutjnl-2020-320730↗
  40. Needle-compatible miniaturized optoelectronic sensor for pancreatic cancer detection. Co-author DOI 10.1126/sciadv.abc1746↗
  41. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAP… Co-author DOI 10.1136/gutjnl-2019-319352↗
  42. Correction: Management of patients with increased risk for familial pancreatic cancer: updated recommendations for the international cancer of the pancreas scr… Co-author DOI 10.1136/gutjnl-2019-319352corr1↗
  43. Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma. Co-author DOI 10.3322/caac.21626↗
  44. Impacting Pancreatic Cancer Therapy in Heterotypic in Vitro Organoids and in Vivo Tumors with Specificity-Tuned, NIR-Activable Photoimmunonanoconjugates: Towar… Co-author DOI 10.1021/acs.nanolett.9b00859↗
  45. A Phase I/II Open-Label Multicenter Single-Arm Study of FABLOx (Metronomic 5-Fluorouracil Plus nab-Paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin) in Pat… Co-author DOI 10.1089/pancan.2019.0012↗
  46. Evaluating Susceptibility to Pancreatic Cancer: ASCO Provisional Clinical Opinion. Co-author DOI 10.1200/jco.18.01489↗
  47. Profiling Heterogeneous Circulating Tumor Cells (CTC) Populations in Pancreatic Cancer Using a Serial Microfluidic CTC Carpet Chip. Co-author DOI 10.1002/adbi.201800228↗
  48. Usp9x Promotes Survival in Human Pancreatic Cancer and Its Inhibition Suppresses Pancreatic Ductal Adenocarcinoma In Vivo Tumor Growth. Co-author DOI 10.1016/j.neo.2017.11.007↗
  49. Integrating single-cell RNA-Seq with spatial transcriptomics in pancreatic ductal adenocarcinoma using multimodal intersection analysis Co-author DOI 10.1101/254375↗
  50. HNF1A is a novel oncogene that regulates human pancreatic cancer stem cell properties. Last author DOI 10.7554/elife.33947↗

Trials 1

  1. Pancreatic Cancer Early Detection Consortium Study chair NCT04970056↗

Grants 9

  1. Biomarker Validation in Pancreatic Cystic Neoplasms U01CA282272↗
  2. POLQ Synthetic Lethality in HR-Deficient Pancreatic Adenocarcinoma R01CA245005↗
  3. Regulation of Pancreatic Oncogenesis by the Gut Microbiome R01CA206105↗
  4. Early Detection Biomarkers in Pancreatic Adenocarcinoma R01CA131045↗
  5. 2017 Pancreatic Diseases Gordon Research Conference R13DK114948↗
  6. Translational Research in GI Cancer P50CA130810↗
  7. 2015 Pancreatic Diseases Gordon Research Conference R13DK106939↗
  8. Innovative Grant: Diane Simeone (mesenchymal stem cells in pancreatic cancer) AWARD pancan:2014-diane-simeone-md-innovative-grant-diane-simeone-mesenchym
  9. Targeting Notch Signaling in Pancreatic Cancer Stem Cells AWARD pancan:2010-diane-simeone-md-targeting-notch-signaling-in-pancreatic-

Closest collaborators

The 25 strongest of 361 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jessica N. Everett · 10 shared papers, 1 shared grant, 2021–2026 · strength 2.63
  2. Aristotelis Tsirigos · 3 shared papers, 1 shared grant, 2023–2026 · strength 1.47
  3. Randall E. Brand · 11 shared papers, 2011–2026 · strength 1.42
  4. Fay Kastrinos · 8 shared papers, 2020–2026 · strength 1.13
  5. Tamas A. Gonda · 6 shared papers, 2021–2025 · strength 1.03
  6. Aimee Lee Lucas · 7 shared papers, 2020–2026 · strength 0.95
  7. Agnel Sfeir · 1 shared grant, 2024 · strength 0.91
  8. George Zogopoulos · 6 shared papers, 2021–2026 · strength 0.89
  9. Salvatore Paiella · 6 shared papers, 2021–2026 · strength 0.88
  10. Bryson W. Katona · 5 shared papers, 2021–2026 · strength 0.79
  11. Paul E. Oberstein · 5 shared papers, 2021–2024 · strength 0.76
  12. Gregor Werba · 5 shared papers, 2021–2024 · strength 0.74
  13. Sonia S. Kupfer · 5 shared papers, 2021–2026 · strength 0.71
  14. Rosalie C. Sears · 4 shared papers, 2021–2026 · strength 0.64
  15. Teresa A. Brentnall · 7 shared papers, 2015–2024 · strength 0.62
  16. Despoina Kalfakakou · 4 shared papers, 2023–2026 · strength 0.61
  17. Jennifer B. Permuth · 4 shared papers, 2021–2026 · strength 0.57
  18. Talia Golan · 4 shared papers, 2021–2024 · strength 0.52
  19. Marcia Irene Canto · 5 shared papers, 2015–2022 · strength 0.51
  20. Elena M. Stoffel · 5 shared papers, 2019–2024 · strength 0.50
  21. James J. Farrell · 4 shared papers, 2020–2024 · strength 0.50
  22. Julie Earl · 3 shared papers, 2023–2026 · strength 0.49
  23. Raymond Couric Wadlow · 3 shared papers, 2023–2026 · strength 0.48
  24. Marina Pasca di Magliano · 8 shared papers, 2011–2021 · strength 0.47
  25. Ken Herrmann · 2 shared papers, 2023 · strength 0.46

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.